Glenmark Pharmaceutical’s US Unit Launches Latanoprost Ophthalmic Solution

Glenmark Pharmaceuticals Inc., USA, has launched Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) in the US market. This product is bioequivalent and therapeutically equivalent to Xalatan® Ophthalmic Solution, 0.005%, manufactured by Upjohn US 2 LLC.

Market Size and Competition

The market for Xalatan® Ophthalmic Solution saw annual sales of approximately $113.5 million for the 12-month period ending December 2024, according to the reports. Latanoprost is commonly prescribed for glaucoma and ocular hypertension, conditions that lead to increased pressure in the eye. 

With multiple generic versions already available, Glenmark enters a competitive segment where pricing and distribution strength will determine market share.

Glenmark’s Ophthalmic Portfolio

This is Glenmark’s fourth ophthalmic product in the US, adding to its growing presence in this segment. Marc Kikuchi, President & Business Head, North America, noted that the company is expanding its ophthalmic portfolio to strengthen its market position in the category.

Global Presence

Glenmark Pharmaceuticals Ltd. is present in branded, generic, and OTC segments across respiratory, dermatology, and oncology. The company has 11 manufacturing facilities across four continents.

Ranked among the Top 100 bio-pharmaceutical companies by sales in 2023, Glenmark was also placed in the Top 50 generics and biosimilar companies by sales in 2024. It is one of only two Indian pharmaceutical firms with Science Based Target Initiative (SBTi)-approved greenhouse gas (GHG) emission reduction targets as of 2023.

Market Reaction

Shares of Glenmark Pharmaceuticals traded 2.93% lower at ₹1,410 on the BSE around 9:57 AM following the announcement. The stock has dropped 12.18% in the past month but is still up 67% over the past year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing